Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

95 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Antigen processing influences HIV-specific cytotoxic T lymphocyte immunodominance.
Tenzer S, Wee E, Burgevin A, Stewart-Jones G, Friis L, Lamberth K, Chang CH, Harndahl M, Weimershaus M, Gerstoft J, Akkad N, Klenerman P, Fugger L, Jones EY, McMichael AJ, Buus S, Schild H, van Endert P, Iversen AK. Tenzer S, et al. Among authors: friis l. Nat Immunol. 2009 Jun;10(6):636-46. doi: 10.1038/ni.1728. Epub 2009 May 3. Nat Immunol. 2009. PMID: 19412183
Outpatient Management of Patients Conditioned with Fludarabine and Treosulfan prior to Allogeneic Hematopoietic Cell Transplantation.
Schovsbo JS, Kjeldsen L, Nørskov KH, Sengeløv H, Kornblit BT, Schjødt I, Petersen SL, Nygaard M, Andersen NS, Mortensen BK, Friis LS. Schovsbo JS, et al. Among authors: friis ls. Transplant Cell Ther. 2024 Nov 9:S2666-6367(24)00746-2. doi: 10.1016/j.jtct.2024.11.001. Online ahead of print. Transplant Cell Ther. 2024. PMID: 39522721 Free article.
Evaluation and management of hepatic dysfunction, portal hypertension and portal/splanchnic vein thrombosis in patients with myelofibrosis undergoing allogeneic haematopoietic cell transplantation: A practice based survey on behalf of the Chronic Malignancies Working Party of the EBMT.
Battipaglia G, Polverelli N, Tuffnell J, Chiusolo P, Robin M, Gambella M, Broers A, Sala E, Passweg J, Furst S, Friis LS, Dulery R, de Witte M, Srour M, Finazzi MC, Wehr C, Nagler A, Richardson D, Bethge W, Clark A, Drozd-Sokolowska J, Raj K, Czerw T, Hernández-Boluda JC, McLornan DP. Battipaglia G, et al. Among authors: friis ls. Curr Res Transl Med. 2024 Oct 25;73(1):103476. doi: 10.1016/j.retram.2024.103476. Online ahead of print. Curr Res Transl Med. 2024. PMID: 39461096 Free article.
Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With NPM1 and FLT3 Mutations.
Russell NH, Wilhelm-Benartzi C, Othman J, Dillon R, Knapper S, Batten LM, Canham J, Hinson EL, Betteridge S, Overgaard UM, Gilkes A, Potter N, Mehta P, Kottaridis P, Cavenagh J, Hemmaway C, Arnold C, Freeman SD, Dennis M; PORTEC Study Group. Russell NH, et al. J Clin Oncol. 2024 Apr 1;42(10):1158-1168. doi: 10.1200/JCO.23.00943. Epub 2024 Jan 12. J Clin Oncol. 2024. PMID: 38215358 Clinical Trial.
Donor Lymphocyte Infusion Is a Feasible Way to Improve Survival in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes Who Relapse after Allogeneic Stem Cell Transplantation.
Minculescu L, Reekie J, Petersen SL, Kornblit BT, Schjoedt I, Andersen NS, Andersen LP, Fischer-Nielsen A, Haastrup EK, Friis LS, Sengelov H. Minculescu L, et al. Among authors: friis ls. Acta Haematol. 2024;147(3):325-332. doi: 10.1159/000534315. Epub 2023 Oct 12. Acta Haematol. 2024. PMID: 37827141
Triple-Drug Graft-versus-Host Disease Prophylaxis after HLA-Matched Unrelated Donor Nonmyeloablative Allogenic Hematopoietic Stem Cell Transplantation.
Wegener A, Andersen NS, Friis LS, Petersen SL, Schjødt I, Kornblit B, Sengeløv H, Gjærde LK. Wegener A, et al. Among authors: friis ls. Transplant Cell Ther. 2023 Sep;29(9):575.e1-575.e6. doi: 10.1016/j.jtct.2023.05.022. Epub 2023 Jun 9. Transplant Cell Ther. 2023. PMID: 37301257 Free article. Clinical Trial.
Pretransplantation Plasma ST2 Level as a Prognostic Biomarker of 1-Year Nonrelapse Mortality in Allogeneic Hematopoietic Cell Transplantation.
Gjærde LK, Ostrowski SR, Schierbeck F, Andersen NS, Friis LS, Kornblit B, Petersen SL, Schjødt I, Sengeløv H. Gjærde LK, et al. Among authors: friis ls. Transplant Cell Ther. 2023 Feb;29(2):97.e1-97.e6. doi: 10.1016/j.jtct.2022.11.009. Epub 2022 Nov 11. Transplant Cell Ther. 2023. PMID: 36375798 Free article.
95 results